Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNB1 | Q14721 | 4/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | KCNK2 | O95069 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | C5 | P01031 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | ESRRA | P11474 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6565938 | 0.86 | CNR1 (0.44) | LMNAMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL6568107 | 0.85 | PKM (0.48) | LMNAMEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL6565854 | 0.84 | KMT2A (0.46) | LMNAMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL6564631 | 0.83 | EPHX1 (0.47) | C5ESRRA | |
| SCHEMBL6564651 | 0.83 | NPSR1 (0.46) | KCNB1KCNA5KCNH2KCNK2LMNA | |
| SCHEMBL6564429 | 0.82 | KMT2A (0.49) | LMNAMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL6567867 | 0.82 | KMT2A (0.44) | LMNAMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL6565928 | 0.82 | MCHR1 (0.46) | LMNAMEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL6564786 | 0.82 | KMT2A (0.61) | LMNAMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL6567969 | 0.80 | CASR (0.53) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | HRH4, HRH2, HRH1 | KCNB1 436/4885KCNA5 249/4885KCNH2 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.